Recent Articles:
ACT Announces Data and Safety Monitoring Board (DSMB) Approval
Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Data and Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the Company’s three
Sample Preparation: A Rapidly Growing Industry
Pressure BioSciences Inc. (OTCQB: PBIO), a developer of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology (“PCT”), operating in the same industry as companies like Qiagen NV (NASDAQ: QGEN) and Becton, Dickenson
BioTime and Subsidiary LifeMap Sciences Announce Agreement to Acquire XenneX, Inc.
LifeMap Sciences will use new family of online databases to promote the sale of stem cell research products and for discovery of regenerative medicine therapeutic products, based on BioTime’s ACTCellerate(TM) human progenitor cell lines BioTime,
Stem Cell Agency Unveils Strategic Partnership Fund to Increase Investment and Engagement with Industry in Stem Cell Therapies for Patients
The state’s stem cell agency, the California Institute for Regenerative Medicine (CIRM) is committing up to $30 million to a Strategic Partnership Awards Initiative to attract industry engagement and investment in CIRM-funded stem cell research.
Pressure BioSciences (PBIO) Deal Lauded by Zacks Research
Pressure BioSciences, Inc. (OTCQB: PBIO), a developer of proprietary lab instrumentation and associated consumables based on its game changing Pressure Cycling Technology (PCT), providing equipment to companies like Thermo Fisher Scientific (NYSE: TMO) and Amgen Inc. (NASDAQ: AMGN),
Investor Stem Cell Encourages Public to Vote
Investor Stem Cell’s Jason Gruner recently issued a plea to the public to sign the petition for Advancing Breakthrough Therapies for Patients Act of 2012. Below is the transcript of the e-mail that the company
Accelr8 (AXK): Award-Winning Technology Could Unlock Tremendous Value
Accelr8 Technology Corporation (AMEX: AXK), a developer of innovative materials and instrumentation to rapidly identify infectious pathogens, operating in the same basic industry as companies like PolyMedix Inc. (OTCBB: PYMX) and Becton Dickinson and Co.
VistaGen Licenses Breakthrough Stem Cell Culture Technology
VistaGen Therapeutics, Inc. (OTC.BB: VSTA.OB) (OTCQB: VSTA.OB), a biotechnology company applying stem cell technology for drug rescue and cell therapy, has licensed breakthrough stem cell culture technology from the McEwen Centre for Regenerative Medicine located at the University Health
OxySure Systems (OXYS) Develops the Next “AED” or “Fire Extinguisher”
OxySure Systems Inc. (OTCBB: OXYS), a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions, similar to companies like Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) and ZOLL Medical Corporation
Cytomedix Stands Taller than Competition with New Treatment for Diabetic Foot Ulcers and More
The biotechnology industry is thriving and one of the fastest growing markets available for investment today. Within the industry, the diabetes sector is outpacing most others. In late February, leading business intelligence provider GBI Research
Cardium’s (CXM) MedPodium Nutra-Apps® Expands Distribution
Cardium Therapeutics (NYSE Amex: CXM), a health sciences and regenerative medicine company focused on the acquisition of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs and
Stem Cell Headlines Highlight Importance of FDA Decisions to Athersys (ATHX) and Others
Companies mentioned in this article include Neuralstem Inc. (AMEX: CUR), StemCells Inc. (NASDAQ: STEM), and Athersys Inc. (NASDAQ: ATHX). There’s no arguing that stem cells therapies have been a hot button topic of controversy for